Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT-Reference-Cited by-同舟云学术

Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT

Published:2020-08-05 Issue:2 Volume:56 Page:334-346
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Najima Yuho^ORCID,Sadato Daichi,Harada Yuka^ORCID,Oboki Keisuke^ORCID,Hirama Chizuko,Toya Takashi^ORCID,Doki Noriko,Haraguchi Kyoko,Yoshifuji Kota,Akiyama Megumi,Inamoto Kyoko,Igarashi Aiko,Kobayashi Takeshi,Kakihana Kazuhiko^ORCID,Okuyama Yoshiki,Sakamaki Hisashi,Harada Hironori,Ohashi Kazuteru

Funder

Clinical Research Fund of Tokyo Metropolitan Government

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-020-01016-9.pdf

Reference53 articles.

1. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

2. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730–8.

3. Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematol. 2015;2:e384–92.